Estradiol valerate/testosterone enanthate

Estradiol valerate /
testosterone enanthate

Estradiol valerate (top) and testosterone enanthate (bottom)
Combination of
Estradiol valerate	Estrogen
Testosterone enanthate	Androgen; Anabolic steroid
Clinical data
Trade names	Deladumone, Despamen, Ditate, Ditate-DS, Gravignost, Primodian Depot, Valertest, others
Other names	EV/TE; TEEV
Routes of administration	Intramuscular injection
Identifiers
CAS Number	979-32-8  Y 315-37-7  Y
PubChem CID	69248505
UNII	OKG364O896 7Z6522T8N9  Y

Estradiol valerate/testosterone enanthate (EV/TE), sold under the brand names Primodian Depot and Ditate among others, is an injectable combination medication of estradiol valerate (EV), an estrogen, and testosterone enanthate (TE), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women. ^{[1] [2]} The medication is also used to suppress lactation in postpartum women (brand name Deladumone). ^{[3] [4] [5] [6]}

Ditate was provided in the form of multi-use 10 mL vials containing 4 mg/mL EV and 90 mg/mL TE in an oil solution and was administered by intramuscular injection at regular intervals. ^[7] Conversely, another preparation, Ditate-DS, was provided in the form of single-use 2 mL vials containing 8 mg/mL EV and 180 mg/mL TE in an oil solution, and was administered as a single intramuscular injection. ^[7] Another product, Primodian Depot, was provided in the form of 1 mL ampoules containing 4 mg/mL EV (3.0 mg/mL free estradiol) and 90.3 mg/mL TE (65 mg/mL free testosterone) in an oil solution, and was administered by intramuscular injection once every 4 to 6 weeks. ^{[8] [9] [10] [11]} The elimination half-life of EV in oil by intramuscular injection is approximately 4 or 5 days. ^[12] Similarly, the elimination half-life of TE in oil by intramuscular injection is approximately 4 or 5 days. ^[13] EV/TE reportedly has a duration of about 21 days. ^[14]

Deladumone OB was a double-dosage formulation of Deladumone, which was intended to provide the same dosage with a smaller injection volume. ^[15]

Primodian Depot was introduced for medical use by 1955. ^[16] An oral tablet product with the similar brand name of Primodian, containing ethinylestradiol and methyltestosterone, was marketed around the same time, and should not be confused with the injectable Primodian Depot. ^[8] EV/TE was discontinued in the United States by 2011. ^[17] EV/TE has been discontinued in most other countries as well, but formulations of EV/TE continue to be marketed in a few countries, including Japan, Mexico, Peru, and Taiwan. ^{[18] [19] [20]}

• v
• t
• e

Androgen replacement therapy formulations and dosages used in women

Route	Medication	Major brand names	Form	Dosage
Oral	Testosterone undecanoate	Andriol, Jatenzo	Capsule	40–80 mg 1x/1–2 days
	Methyltestosterone	Metandren, Estratest	Tablet	0.5–10 mg/day
	Fluoxymesterone	Halotestin	Tablet	1–2.5 mg 1x/1–2 days
	Normethandrone a	Ginecoside	Tablet	5 mg/day
	Tibolone	Livial	Tablet	1.25–2.5 mg/day
	Prasterone (DHEA) b	–	Tablet	10–100 mg/day
Sublingual	Methyltestosterone	Metandren	Tablet	0.25 mg/day
Transdermal	Testosterone	Intrinsa	Patch	150–300 μg/day
		AndroGel	Gel, cream	1–10 mg/day
Vaginal	Prasterone (DHEA)	Intrarosa	Insert	6.5 mg/day
Injection	Testosterone propionate a	Testoviron	Oil solution	25 mg 1x/1–2 weeks
	Testosterone enanthate	Delatestryl, Primodian Depot	Oil solution	25–100 mg 1x/4–6 weeks
	Testosterone cypionate	Depo-Testosterone, Depo-Testadiol	Oil solution	25–100 mg 1x/4–6 weeks
	Testosterone isobutyrate a	Femandren M, Folivirin	Aqueous suspension	25–50 mg 1x/4–6 weeks
	Mixed testosterone esters	Climacterona	Oil solution	150 mg 1x/4–8 weeks
		Omnadren, Sustanon	Oil solution	50–100 mg 1x/4–6 weeks
	Nandrolone decanoate	Deca-Durabolin	Oil solution	25–50 mg 1x/6–12 weeks
	Prasterone enanthate a	Gynodian Depot	Oil solution	200 mg 1x/4–6 weeks
Implant	Testosterone	Testopel	Pellet	50–100 mg 1x/3–6 months
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes:a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.

See also

• List of combined sex-hormonal preparations

References

1. Shellenberger TE (6 December 2012). "Pharmacology of estrogens". In Notelovitz M, van Keep PA (eds.). The Climacteric in Perspective: Proceedings of the Fourth International Congress on the Menopause, held at Lake Buena Vista, Florida, October 28–November 2, 1984. Springer Science & Business Media. pp. 397–. doi:10.1007/978-94-009-4145-8_36. ISBN   978-94-009-4145-8.
2. Kahr H, Müller HA (1956). "Das Klimakterium". Konservative Therapie der Frauenkrankheiten. Springer. pp. 85–102. doi:10.1007/978-3-7091-5694-0_2. ISBN   978-3-7091-5696-4.
3. McNeilly AS (2011). "Physiology of lactation". Journal of Biosocial Science. 9 (S4): 5–21. doi:10.1017/S0021932000023804. ISSN   0021-9320. S2CID   24614184.
4. Vorherr H (July 1972). "Suppression of postpartum lactation". Postgraduate Medicine. 52 (1): 145–152. doi:10.1080/00325481.1972.11713186. PMID   5037562.
5. Vorherr H (2 December 2012). "Supression of Lactation". The Breast: Morphology, Physiology, and Lactation. Elsevier Science. pp. 200–203. ISBN   978-0-323-15726-1.
6. Copeland Jr WE (1986). "Lactation Suppressants.". Drug Therapy in Obstetrics and Gynecology. p. 241.
7. de Haen P (1972). "Drugs Released for Clinical Use". The Journal of Clinical Pharmacology and New Drugs. 12 (1): 58–60. doi:10.1002/j.1552-4604.1972.tb00038.x. ISSN   0021-9754.
8. Hager HH, Kern W, List PH, Roth HJ (29 July 2013). "Gestagene, Progestagene". Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). Springer-Verlag. pp. 142, 156, 185. ISBN   978-3-662-25655-8.
9. Saure A (11 November 2013). "Hormonpräparate, die zur Behandlung der Wechseljahre eingesetzt werden". Die Wechseljahre der Frau: Hormone — Präparate — Therapien. Springer-Verlag. pp. 157–. ISBN   978-3-0348-6676-7.
10. Arends G, Zörnig H, Hager H, Frerichs G, Kern W (14 December 2013). "Hormone". Hagers Handbuch der pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte u. Medizinalbeamte. Springer-Verlag. pp. 1164–. ISBN   978-3-662-36329-4.
11. Kaiser R (2 July 2013). "Ovar". In Buchborn E, Jahrmärker H, Karl HJ, Martini GA, Müller W, Riecker G, Schwiegk H, Siegenthaler W, Stich W (eds.). Therapie innerer Krankheiten. Springer-Verlag. pp. 405–. ISBN   978-3-662-10489-7.
12. Düsterberg B, Nishino Y (December 1982). "Pharmacokinetic and pharmacological features of oestradiol valerate". Maturitas. 4 (4): 315–324. doi:10.1016/0378-5122(82)90064-0. PMID   7169965.
13. Luetjens CM, Wistuba J, Weinbauer G, Nieschlag E (2007). "The Leydig Cell as a Target for Male Contraception". In Payne AH, Hardy MP (eds.). The Leydig Cell in Health and Disease. Contemporary Endocrinology. Humana Press. pp. 415–442. doi:10.1007/978-1-59745-453-7_29. ISBN   978-1-58829-754-9.
14. Ufer J (1 January 1978). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis[Hormone Therapy in Gynecology: Principles and Practice] (in German) (5th ed.). de Gruyter. p. 276. ISBN   978-3110066647. OCLC   924728827.
15. Physicians Desk Reference to Pharmaceutical Specialties and Biologicals. Medical Economics. 1971. p. 1262. Deladumone OB contains the same hormonal agents as Deladumone (Testosterone Enanthate and Estradiol Valerate Injection) but at twice the potency, in order to provide a high dosage concentration in a low volume.
16. Geburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die Praxis. Georg Thieme Verlag. 1955. pp. 1061–1062.
17. Food and Drug Administration (2011). Approved Drug Products with Therapeutic Equivalence Evaluations - FDA Orange Book 31st Edition (2011): FDA Orange Book 31st Edition (2011). DrugPatentWatch.com. pp. 586–. ISBN   978-1-934899-81-6.
18. "Estradiol". Drugs.com.
19. Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. pp. 2100, 2124–2125. ISBN   978-0-85369-840-1.
20. "IBM Watson Health Products: Please Login". www.micromedexsolutions.com.